SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (10970)11/11/1997 5:35:00 AM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
chirodoc, Pramlintide is not really stiff competition for Targretin and other rexinoids. So far it hasn't been showed to significantly help type II for extended time periods, although the lack of proof may be due to the clinical trial design. However, even if it does, most diabetics would rather treat the cause than the result of their disease. Pramlimtide in many respects is like a weaker version of insulin. Such injectables will eventually become obsolete and markets will shrink, not grow, which is one of the reasons LLY signed their deal with LGND (and I wouldn't be surprised if JNJ were talking to AGN).



To: chirodoc who wrote (10970)11/11/1997 9:29:00 AM
From: tonyt  Read Replies (1) | Respond to of 32384
 
<<<<<<< The Barron's article on AMLN really didn't have anything new, but I do expect it to attract some buyers. However, since nothing has changed, such jumps usually don't hold very long.

Will the three rumored Ligand articles have anything new? If not, selling on the 'jump', and buying back later might be something to consider.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News